FDA delays decision on Moderna's RSV shot until the end of May

What difference does a few weeks make?

Moderna will have to consider that after receiving word that the FDA will not meet a May 12 decision date for its respiratory syncytial virus (RSV) vaccine candidate. The vaccine maker said Friday that it was recently notified by the agency that, due to “administrative constraints,” a decision on mRNA-1345 has been pushed until the end of the month.